Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31698371 | 0.80 | EPRS1 (0.32) | — | |
| SCHEMBL31698874 | 0.73 | CYP1A2 (0.37) | ESR1MAP3K12 | |
| SCHEMBL31698406 | 0.72 | AR (0.36) | MAP3K12 | |
| SCHEMBL31349498 | 0.69 | AR (0.36) | — | |
| SCHEMBL31349612 | 0.69 | AR (0.33) | — | |
| SCHEMBL31698360 | 0.67 | ABL1 (0.39) | — | |
| SCHEMBL31583384 | 0.66 | ESR1 (0.38) | ESR1 | |
| SCHEMBL31698750 | 0.65 | CSNK1E (0.33) | — | |
| SCHEMBL23467043 | 0.63 | NT5E (0.38) | ESR1 | |
| SCHEMBL26024416 | 0.63 | TRPA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | ESR1 3078/4885MAP3K12 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.